Cambridge UK, 14th June 2011 - Antitope Ltd., Cambridge UK (“Antitope”) today announced a research agreement with the Institute for Medical Microbiology, Immunology and Hygiene, University of Cologne, Germany (“IMMIH“) for the generation of monoclonal therapeutic antibodies for use in polyvalent vaccines against antibiotic-resistant bacterial infections. Under this agreement, Antitope will apply its Composite Human AntibodyTM technology to humanize three murine monoclonal antibodies. The resulting humanized antibodies will be devoid of T cell epitopes with a reduced risk of clinical immunogenicity.
“"We are delighted to be working with such an esteemed institution in order to generate cutting-edge therapeutic antibodies,” said Dr Matthew Baker, Chief Scientific Officer and co-founder of Antitope, adding, "This agreement combines our partners’ expertise in development of novel vaccines with Antitope’s expertise in engineering humanized antibodies to create new strategies in vaccine design that may have a significant impact on as yet untreatable diseases."
About Antitope Ltd.
Antitope Ltd. is a privately-held Cambridge UK-based biotechnology company specializing in immunogenicity testing and the engineering of therapeutic antibodies/proteins with reduced immunogenicity. Antitope’s proprietary EpiScreenTM technology enables preclinical analysis of the potential for immunogenicity of therapeutic antibodies and proteins. Antitope's proprietary Composite Human AntibodyTM technology results in the generation of humanized antibodies devoid of T cell epitopes. Antitope has established multiple commercial relationships with leading biotechnology and pharmaceutical companies worldwide.
About IMMIH, University of Cologne
The Institute for Medical Microbiology, Immunology and Hygiene at the University of Cologne provides medical care for the patients of the University Hospital in Cologne. IMMIH is a teaching institute with great emphasis on research in the field of infection and immunity. More than 10 independent research groups tackle microbiological challenges like the development of antibiotic resistance by human bacterial pathogens, nosocomial infections, or host factors determining the course of infectious diseases. The generation of vaccines against multi-resistant bacterial pathogens is one of our major strategic goals, which calls for collaboration with expert pharmaceutical companies.
Neil Butt PhD
Tel: +44 1223 496190